Real-life durability and virological outcomes of doravirine in people with multidrug-resistant HIV.

Authors

Tommaso Clemente, Nicolò Capra, Vincenzo Malagnino, Riccardo Lolatto, Sergio Lo Caputo, Laura Comi, Andrea Giacomelli, Giovanni Cenderello, Manuela Colafigli, Stefano Rusconi, Maurizio Zazzi, Antonella Castagna, PRESTIGIO Study Group

Published in

AIDS (London, England). Volume 40. Issue 11. Pages 1769-1773. Nov 01, 2026. Epub Oct 01, 2026.

Abstract

Outcomes of doravirine in heavily treatment-experienced people with HIV (PWH) remain poorly defined, despite in vitro activity against multiple resistance patterns. In this multicenter cohort of 4-class drug-resistant PWH, we evaluated durability and outcomes of doravirine-containing regimens. Among 52 individuals, doravirine was maintained in 63.5% over a median of 2.4 years. Viral load <50 copies/ml was achieved in 58.6% of viremic initiators, but maintained in 82.6% of nonviremics. Findings support genotype-informed doravirine use within complex regimens, particularly for switching in nonviremics.

PMID:
42826227
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.